Discover why biomarker intelligence is essential for precision drug development, improving target selection, patient stratification, and clinical trial success.
Learn how better data helps pharmaceutical companies identify the right drug licensing opportunities through clinical drug development, development of drug insights, and API drug development intelligence.
It's the structured path a molecule follows from lab to market: preclinical research, Phase I (safety), Phase II (efficacy and dosing), Phase III (large-scale confirmation), regulatory review, and Phase IV post-market monitoring. As of 2026, nearly half of the roughly 23,000 active global pipeline drugs are still in the preclinical stage alone.
Here is a number that should stop you: more than 10,000 rare diseases have been identified globally, yet fewer than 500 have an approved treatment.
Backed by latest FDA data, this article analyzes approval trends, clinical challenges, and innovation drivers in pharmaceutical R&D.
21 September 2026
15 September 2026
1 September 2026
25 August 2026
18 August 2026
